ENSIKLOPEDIA

Tekan Enter untuk memulai pencarian cepat.

Kembali ke Ensiklopedia Arsip Wikipedia Indonesia

Izenivetmab

Veterinary medication

Pharmaceutical compound

Izenivetmab
Monoclonal antibody
Type	Whole antibody
Target	Nerve growth factor (NGF)
Clinical data
Trade names	Lenivia
Other names	ZTS-00075623
Routes of administration	Subcutaneous
ATCvet code	QN02BG93 (WHO)
Legal status
Legal status	CA: ℞-only EU: Rx-only^[1]
Identifiers
CAS Number	2447755-72-6
UNII	UR46CWR8UW
Chemical and physical data
Formula	C₆₅₇₀H₁₀₀₇₈N₁₇₅₀O₂₀₂₂S₄₈
Molar mass	147472.00 g·mol⁻¹

Izenivetmab, sold under the brand name Lenivia, is a canine monoclonal antibody medication used for the alleviation of pain associated with osteoarthritis in dogs.^[2]

Izenivetmab was authorized for veterinary use in Canada in October 2025,^[3] and in the European Union in November 2025.^[4]

Medical uses

Izenivetmab is indicated for the alleviation of pain associated with osteoarthritis in dogs.^[5]

Society and culture

Legal status

Izenivetmab was authorized for veterinary use in Canada in October 2025,^[3] and in the European Union in November 2025.^[4]

Names

Izenivetmab is the international nonproprietary name.^[6]

Izenivetmab is sold under the brand name Lenivia.^[3]^[4]

References

↑ "Lenivia EPAR". European Medicines Agency (EMA). 10 October 2025. Retrieved 22 December 2025.
↑ "Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 7-9 October 2025". European Medicines Agency (EMA). 10 October 2025. Retrieved 22 December 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1 2 3 "Zoetis Announces Health Canada Approval of Lenivia (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs" (Press release). Zoetis. 15 October 2025. Retrieved 22 December 2025.
1 2 3 "Zoetis Receives European Commission Marketing Authorization for Lenivia (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs" (Press release). Zoetis. 26 November 2025. Retrieved 22 December 2025.
↑ "Lenivia 0.5 mg". European Medicines Agency (EMA). 20 November 2025. Retrieved 22 December 2025.
↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). 2022. hdl:10665/363551.

External links

"Izenivetmab ( Code - C188639 )". EVS Explore.

Analgesics (N02A, N02B)

Opioids

Opiates/opium	Codeine^# +aspirin +paracetamol Morphine^# (+naltrexone) Opium Laudanum Paregoric
Semisynthetic	Acetyldihydrocodeine Benzylmorphine Buprenorphine (+naloxone) Butorphanol Desomorphine Dihydrocodeine (+paracetamol) Dihydromorphine Etorphine Ethylmorphine Hydrocodone (+paracetamol, +ibuprofen, +aspirin) Hydromorphinol Hydromorphone Levorphanol Metopon Nalbuphine Nicocodeine Nicodicodine Nicomorphine Oxycodone (+paracetamol, +aspirin, +ibuprofen, +naloxone, +naltrexone) Oxymorphone Papaveretum Thebacon
Synthetic	Alfentanil Alphaprodine Anileridine Bezitramide Carfentanil Dextromoramide Dextropropoxyphene Dezocine Dimenoxadol Dipipanone Ethoheptazine Fentanyl^# (+fluanisone) Ketobemidone Lofentanil Meptazinol Methadone^# NFEPP Norpipanone Oliceridine Pentazocine Pethidine (meperidine) Phenadoxone Phenazocine Phenoperidine Piminodine Piritramide Proheptazine Propiram Remifentanil Sufentanil Tapentadol Tegileridine Tilidine Tramadol (+celecoxib, +paracetamol) Viminol

Paracetamol-type

Acetanilide^‡
Bucetin^‡
Butacetin^‡
Paracetamol (acetaminophen)^#
Parapropamol^‡
Phenacetin^‡
Propacetamol^‡

NSAIDs

Propionates	Benoxaprofen ^‡ Fenoprofen Flurbiprofen Ibuprofen^# (Dexibuprofen) (+paracetamol) Ketoprofen (Dexketoprofen) Loxoprofen Naproxen Oxaprozin Suprofen Tiaprofenic acid Zaltoprofen
Oxicams	Isoxicam Lornoxicam Meloxicam Piroxicam Tenoxicam
Acetates	Acemetacin Bromfenac Diclofenac Etodolac Indometacin (Indometacin farnesil) Ketorolac Sulindac Tolmetin Zomepirac ^‡
COX-2 inhibitors	Celecoxib (+tramadol) Etoricoxib Lumiracoxib ^‡ Parecoxib Rofecoxib ^‡ Valdecoxib ^‡
Fenamates	Flufenamic acid Meclofenamic acid Mefenamic acid Tolfenamic acid
Salicylates	Aspirin (acetylsalicylic acid)^# (+paracetamol/caffeine) Aloxiprin Benorylate Carbasalate calcium Choline salicylate Diflunisal Dipyrocetyl Ethenzamide Guacetisal Imidazole salicylate Magnesium salicylate Morpholine salicylate Potassium salicylate Salicin Salicylamide Salsalate Sodium salicylate Wintergreen (methyl salicylate)
Pyrazolones	Aminophenazone^‡ Ampyrone Metamizole (dipyrone) Nifenazone Phenazone Propyphenazone (+paracetamol/caffeine)
Others	Benzydamine Floctafenine Glafenine Nabumetone Nimesulide Proquazone

Cannabinoids

Cannabidiol
Cannabis
Nabilone
Nabiximols
Tetrahydrocannabinol (dronabinol)

Ion channel
modulators

Calcium blockers	Alcohol (ethanol) Gabapentin Gabapentin enacarbil Leconotide Mirogabalin Pregabalin Ziconotide
Sodium blockers	Carbamazepine Lacosamide Local anesthetics (e.g., cocaine, lidocaine) Mexiletine Nefopam Tricyclic antidepressants (e.g., amitriptyline^#) Na_v1.7/1.8-selective: DSP-2230^§ Funapide^§ PF-05089771^§ Suzetrigine
Potassium openers	Flupirtine^‡

Myorelaxants

Carisoprodol
Chlorzoxazone
Cyclobenzaprine
Mephenoxalone
Methocarbamol
Orphenadrine

Others

Analgecine
Analgesic adjuvant
Bedinvetmab
Camphor
Capsaicin
Clonidine
Frunevetmab
Izenivetmab
Ketamine
Menthol
Methoxyflurane
Phenazopyridine
Proglumide
Relfovetmab
Rimazolium
Tanezumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone

Human	Burosumab Denosumab
Humanized	Blosozumab^† Romosozumab

Musculoskeletal

Human	Stamulumab^†

Circulatory

Human	Abelacimab Alirocumab Ascrinvacumab^§ Bentracimab^† Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Marstacimab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab^‡ Imciromab^‡
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Concizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic

Human	Anti-amyloid drugs Aducanumab^‡ Donanemab Gantenerumab^† Lecanemab Erenumab Fasinumab^† Fulranumab Opicinumab
Humanized	Bapineuzumab^† Crenezumab^† Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab^†

Angiogenesis inhibitor

Humanized	Ranibizumab

Growth factor

Human	Bimagrumab Trevogrumab
Humanized	Domagrozumab Landogrozumab Tanezumab
Other	Bedinvetmab Frunevetmab Izenivetmab Relfovetmab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Portal:

Medicine

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

Sumber data: id.wikipedia.org via REST API v1